Trulieve Cannabis (TCNNF) EBITDA (2020 - 2026)

Trulieve Cannabis' EBITDA history runs 7 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• In Q1 2026, EBITDA rose 7.2% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $145.9 million (up 71.63% YoY), while the FY2025 annual figure was $168.7 million, up 13.05% from the prior year.
• EBITDA was $35.7 million for Q1 2026 at Trulieve Cannabis, up from $15.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $61.6 million in Q2 2022 to a low of -$291.3 million in Q2 2023.
• Historically, EBITDA has averaged $11.1 million across 5 years, with a median of $35.7 million in 2026.
• The sharpest annual moves came in 2023 and 2025: EBITDA slumped 573.07% in 2023, then surged 6734.63% in 2025.
• A 5-year view of EBITDA shows it stood at -$2.0 million in 2022, then jumped by 1459.19% to $27.3 million in 2023, then tumbled by 95.21% to $1.3 million in 2024, then soared by 1069.5% to $15.3 million in 2025, then soared by 133.54% to $35.7 million in 2026.
• The last three EBITDA figures came in at $35.7 million (Q1 2026), $15.3 million (Q4 2025), and $42.2 million (Q3 2025), per Business Quant data.